enVVeno Medical (NVNO) Return on Capital Employed (2018 - 2026)

enVVeno Medical's Return on Capital Employed history runs 9 years deep, the most recent figure standing at 77.89% for Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 2126.0% year-over-year to 77.89% in Q1 2026; TTM through Mar 2026 was 77.89%, a 2126.0% decrease from a year earlier, with the FY2025 full-year figure at 59.48%, down 618.0% from the prior year.
• Return on Capital Employed fell to 77.89% in Q1 2026 per NVNO's latest filing, from 72.48% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 35.51% in Q1 2022 and bottomed at 90.59% in Q3 2023.
• The 5-year median for Return on Capital Employed is 59.32% (2022), against an average of 63.28%.
• Across the five-year window, Return on Capital Employed sank 3491 bps in 2022 and surged 3675 bps in 2024, its largest moves.
• Year by year, Return on Capital Employed stood at 59.32% in 2022, then dropped by 15 bps to 68.22% in 2023, then gained by 23 bps to 52.28% in 2024, then plunged by 39 bps to 72.48% in 2025, then dropped by 7 bps to 77.89% in 2026.
• Per Business Quant, the three latest NVNO Return on Capital Employed figures stand at 77.89% (Q1 2026), 72.48% (Q4 2025), and 73.55% (Q3 2025).